Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Carcinoma of the Breast
Interventions: DRUG: Paclitaxel|DRUG: Trastuzumab
Sponsor: Dana-Farber Cancer Institute
Collaborators: Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Genentech, Inc.